The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?

J Arthroplasty. 2015 Feb;30(2):315-9. doi: 10.1016/j.arth.2014.08.032. Epub 2014 Sep 6.

Abstract

The purpose of this study was to determine the percentage of time that patients are therapeutic when prescribed warfarin for chemical thromboprophylaxis following a hip or knee arthroplasty procedure. One hundred eighty-four patients receiving warfarin for 4weeks postoperatively, dosed using a Web-application accounting for patient demographics, INR levels, and concomitant medication use, were included. Patients with a target INR range between 1.7 and 2.7 were therapeutic for only 54.4% of the time (32.5% subtherapeutic, 13.0% supratherapeutic) while patients with a target INR range between 2.0 and 3.0 were therapeutic for only 45.9% of the time (39.2% subtherapeutic, 14.8% supratherapeutic). Patients receiving warfarin for chemical thromboprophylaxis are within their targeted INR range for only a limited period of time during their postoperative course.

Keywords: coumadin; thromboprophylaxis; total knee arthroplasty; venous thromboembolism; warfarin.

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use*
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Arthroplasty, Replacement, Knee / adverse effects*
  • Drug Monitoring
  • Female
  • Humans
  • International Normalized Ratio*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Venous Thrombosis / etiology
  • Venous Thrombosis / prevention & control*
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin